Is ELUT or FOCL more profitable?

Elutia has a net margin of 426.93% compared to FocalTherics' net margin of -56.26%. FocalTherics' return on equity of -248.00% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 426.93% -407.37% -47.08% FocalTherics -56.26% -248.00% -44.69%

Which has higher valuation & earnings, OWLT or ELUT?

Elutia has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Owlet $105.70M 1.37 -$39.68M -$0.75 N/A Elutia $12.29M 3.11 $53.38M $0.95 0.91

Is OWLT or ELUT more profitable?

Elutia has a net margin of 426.93% compared to Owlet's net margin of -8.61%. Elutia's return on equity of -407.37% beat Owlet's return on equity. Company Net Margins Return on Equity Return on Assets Owlet -8.61% -601.24% -15.96% Elutia 426.93% -407.37% -47.08%

Do analysts prefer ELUT or INGN?

Elutia presently has a consensus price target of $6.00, indicating a potential upside of 594.36%. Given Elutia's higher possible upside, analysts clearly believe Elutia is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, ELUT or INGN?

Elutia has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elutia $12.29M 3.11 $53.38M $0.95 0.91 Inogen $348.67M 0.41 -$22.75M -$0.90 N/A

Is ELUT or INGN more profitable?

Elutia has a net margin of 426.93% compared to Inogen's net margin of -6.94%. Inogen's return on equity of -13.17% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 426.93% -407.37% -47.08% Inogen -6.94% -13.17% -8.36%

Is KRMD or ELUT more profitable?

Elutia has a net margin of 426.93% compared to KORU Medical Systems' net margin of -4.03%. KORU Medical Systems' return on equity of -10.63% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets KORU Medical Systems -4.03% -10.63% -6.51% Elutia 426.93% -407.37% -47.08%

Which has better earnings and valuation, APYX or ELUT?

Elutia has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apyx Medical $52.84M 2.43 -$11.21M -$0.20 N/A Elutia $12.29M 3.11 $53.38M $0.95 0.91

Is APYX or ELUT more profitable?

Elutia has a net margin of 426.93% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -14.78% -76.60% -13.91% Elutia 426.93% -407.37% -47.08%

Elutia (ELUT) Competitors

$0.86 -0.02 (-1.81%)

As of 08/31/2026 04:00 PM Eastern

Compare

ELUT vs. FOCL, OWLT, INGN, KRMD, and APYX

Should you buy Elutia stock or one of its competitors? Elutia's main competitors and comparable companies include FocalTherics (FOCL), Owlet (OWLT), Inogen (INGN), KORU Medical Systems (KRMD), and Apyx Medical (APYX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Elutia compare to FocalTherics?

Elutia (NASDAQ:ELUT) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Elutia presently has a consensus price target of $6.00, indicating a potential upside of 594.36%. FocalTherics has a consensus price target of $7.75, indicating a potential upside of 81.50%. Given Elutia's higher probable upside, research analysts plainly believe Elutia is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

74.0% of Elutia shares are owned by institutional investors. Comparatively, 62.7% of FocalTherics shares are owned by institutional investors. 17.8% of Elutia shares are owned by company insiders. Comparatively, 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Elutia has a net margin of 426.93% compared to FocalTherics' net margin of -56.26%. FocalTherics' return on equity of -248.00% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	426.93%	-407.37%	-47.08%
FocalTherics	-56.26%	-248.00%	-44.69%

Elutia has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

In the previous week, FocalTherics had 14 more articles in the media than Elutia. MarketBeat recorded 16 mentions for FocalTherics and 2 mentions for Elutia. Elutia's average media sentiment score of 1.44 beat FocalTherics' score of 0.78 indicating that Elutia is being referred to more favorably in the media.

Company	Overall Sentiment
Elutia	Positive
FocalTherics	Positive

Elutia has higher earnings, but lower revenue than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.11	$53.38M	$0.95	0.91
FocalTherics	$70.53M	2.27	-$29.25M	-$1.03	N/A

Summary

Elutia beats FocalTherics on 10 of the 16 factors compared between the two stocks.

How does Elutia compare to Owlet?

Owlet (NYSE:OWLT) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Elutia has a net margin of 426.93% compared to Owlet's net margin of -8.61%. Elutia's return on equity of -407.37% beat Owlet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Owlet	-8.61%	-601.24%	-15.96%
Elutia	426.93%	-407.37%	-47.08%

Owlet currently has a consensus target price of $15.00, indicating a potential upside of 202.42%. Elutia has a consensus target price of $6.00, indicating a potential upside of 594.36%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Owlet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Elutia had 1 more articles in the media than Owlet. MarketBeat recorded 2 mentions for Elutia and 1 mentions for Owlet. Owlet's average media sentiment score of 1.84 beat Elutia's score of 1.44 indicating that Owlet is being referred to more favorably in the media.

Company	Overall Sentiment
Owlet	Very Positive
Elutia	Positive

Elutia has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$105.70M	1.37	-$39.68M	-$0.75	N/A
Elutia	$12.29M	3.11	$53.38M	$0.95	0.91

Owlet has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Elutia has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

72.6% of Owlet shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 36.2% of Owlet shares are owned by insiders. Comparatively, 17.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Elutia beats Owlet on 9 of the 16 factors compared between the two stocks.

How does Elutia compare to Inogen?

Elutia (NASDAQ:ELUT) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Elutia has a net margin of 426.93% compared to Inogen's net margin of -6.94%. Inogen's return on equity of -13.17% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	426.93%	-407.37%	-47.08%
Inogen	-6.94%	-13.17%	-8.36%

In the previous week, Elutia and Elutia both had 2 articles in the media. Inogen's average media sentiment score of 1.87 beat Elutia's score of 1.44 indicating that Inogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Elutia	Positive
Inogen	Very Positive

Elutia has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Inogen has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

Elutia has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.11	$53.38M	$0.95	0.91
Inogen	$348.67M	0.41	-$22.75M	-$0.90	N/A

74.0% of Elutia shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 17.8% of Elutia shares are owned by company insiders. Comparatively, 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Elutia presently has a consensus price target of $6.00, indicating a potential upside of 594.36%. Given Elutia's higher possible upside, analysts clearly believe Elutia is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Elutia and Inogen tied by winning 8 of the 16 factors compared between the two stocks.

How does Elutia compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Elutia has a net margin of 426.93% compared to KORU Medical Systems' net margin of -4.03%. KORU Medical Systems' return on equity of -10.63% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-4.03%	-10.63%	-6.51%
Elutia	426.93%	-407.37%	-47.08%

58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by insiders. Comparatively, 17.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

KORU Medical Systems currently has a consensus target price of $7.00, indicating a potential upside of 112.12%. Elutia has a consensus target price of $6.00, indicating a potential upside of 594.36%. Given Elutia's higher probable upside, analysts plainly believe Elutia is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, KORU Medical Systems had 1 more articles in the media than Elutia. MarketBeat recorded 3 mentions for KORU Medical Systems and 2 mentions for Elutia. Elutia's average media sentiment score of 1.44 beat KORU Medical Systems' score of 1.22 indicating that Elutia is being referred to more favorably in the news media.

Company	Overall Sentiment
KORU Medical Systems	Positive
Elutia	Positive

Elutia has lower revenue, but higher earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13M	3.69	-$2.64M	-$0.04	N/A
Elutia	$12.29M	3.11	$53.38M	$0.95	0.91

KORU Medical Systems has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Elutia has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Summary

KORU Medical Systems and Elutia tied by winning 8 of the 16 factors compared between the two stocks.

How does Elutia compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Apyx Medical had 1 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Apyx Medical and 2 mentions for Elutia. Elutia's average media sentiment score of 1.44 beat Apyx Medical's score of 1.14 indicating that Elutia is being referred to more favorably in the news media.

Company	Overall Sentiment
Apyx Medical	Positive
Elutia	Positive

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 15.9% of Apyx Medical shares are held by company insiders. Comparatively, 17.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Elutia has a net margin of 426.93% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-14.78%	-76.60%	-13.91%
Elutia	426.93%	-407.37%	-47.08%

Apyx Medical currently has a consensus target price of $6.60, suggesting a potential upside of 116.39%. Elutia has a consensus target price of $6.00, suggesting a potential upside of 594.36%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Elutia has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	2.43	-$11.21M	-$0.20	N/A
Elutia	$12.29M	3.11	$53.38M	$0.95	0.91

Apyx Medical has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Elutia has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Summary

Elutia beats Apyx Medical on 9 of the 17 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELUT vs. The Competition

Export

Metric	Elutia	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.97M	$5.83B	$7.20B	$12.89B
Dividend Yield	N/A	1.75%	2.54%	11.27%
P/E Ratio	0.91	25.97	272.61	25.48
Price / Sales	3.11	71.60	626.66	97.10
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	1.33	6.24	11.05	6.34
Net Income	$53.38M	$149.14M	$3.47B	$349.45M
7 Day Performance	-14.45%	-0.61%	0.25%	-0.65%
1 Month Performance	0.85%	6.50%	8.27%	4.48%
1 Year Performance	-62.10%	5.87%	24.14%	14.89%

Elutia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELUT Elutia	3.426 of 5 stars	$0.86 -1.8%	$6.00 +594.4%	-62.1%	$38.97M	$12.29M	0.91	180	Positive News Short Interest Decrease
FOCL FocalTherics	4.4485 of 5 stars	$4.41 +0.5%	$7.75 +75.7%	N/A	$165.51M	$70.53M	N/A	230
OWLT Owlet	3.4022 of 5 stars	$5.17 -0.6%	$15.00 +190.1%	-34.0%	$151.07M	$105.70M	N/A	106	High Trading Volume
INGN Inogen	1.2069 of 5 stars	$5.56 +0.4%	N/A	-32.8%	$147.56M	$348.67M	N/A	1,030	Positive News
KRMD KORU Medical Systems	4.2259 of 5 stars	$3.21 flat	$7.00 +118.1%	-21.8%	$147.44M	$41.13M	N/A	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELUT) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elutia (ELUT) Competitors